Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker

被引:76
作者
Nijenhuis, S [1 ]
Zendman, AJW [1 ]
Vossenaar, ER [1 ]
Pruijn, GJM [1 ]
vanVenrooij, WJ [1 ]
机构
[1] Univ Nijmegen St Radboud Hosp, Dept Biochem 161, NL-6500 HB Nijmegen, Netherlands
关键词
citrullination; rheumatoid arthritis; anti-CCP antibodies; peptidylarginine deiminase;
D O I
10.1016/j.cccn.2004.07.016
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Rheumatoid arthritis (RA) is a common, systemic autoimmune disease of which the exact etiology is not known. In the past 10 years, substantial progress has been made in the identification of the antigens specifically recognized by the autoantibodies of RA patients. A central factor in this respect is citrullination, a form of post-translational modification that is strongly associated with autoinummity in RA. Here, we summarize and discuss our current knowledge on (i) autoantibody systems in RA, (ii) the occurrence of peptidylarginine deiminases and (iii) citrullinated proteins in natural and diseased environments, and (iv) genetic factors involved in RA that may influence the generation and presentation of citrullinated proteins and the resulting antibody production against these modified proteins. Citrullination of proteins may play a key role in the initiation and/or the progression of RA. The onset of citrulline-specific autoimmunity in RA is probably mediated by both environmental and genetic factors, and future studies will learn whether therapeutic intervention at the level of citrullination may provide new possibilities to treat RA. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:17 / 34
页数:18
相关论文
共 142 条
[11]   Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors [J].
Bas, S ;
Perneger, TV ;
Seitz, M ;
Tiercy, JM ;
Roux-Lombard, P ;
Guerne, PA .
RHEUMATOLOGY, 2002, 41 (07) :809-814
[12]   A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis [J].
Berglin, E ;
Padyukov, L ;
Sundin, U ;
Hallmans, G ;
Stenlund, H ;
van Venrooij, WJ ;
Klareskog, L ;
Dahlqvist, SR .
ARTHRITIS RESEARCH & THERAPY, 2004, 6 (04) :R303-R308
[13]  
Bizzaro N, 2001, CLIN CHEM, V47, P1089
[14]   Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment [J].
Bobbio-Pallavicini, F ;
Alpini, C ;
Caporali, R ;
Avalle, S ;
Bugatti, S ;
Montecucco, C .
ARTHRITIS RESEARCH & THERAPY, 2004, 6 (03) :R264-R272
[15]   Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement [J].
Bombardieri, M ;
Alessandri, C ;
Labbadia, G ;
Iannuccelli, C ;
Carlucci, F ;
Riccieri, V ;
Paoletti, V ;
Valesini, G .
ARTHRITIS RESEARCH & THERAPY, 2004, 6 (02) :R137-R141
[16]  
CHAPUYREGAUD S, 2003, ARTHRITIS RES THE S1, V5, P5
[17]   Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6 [J].
Chavanas, S ;
Méchin, MC ;
Takahara, H ;
Kawada, A ;
Nachat, R ;
Serre, G ;
Simon, M .
GENE, 2004, 330 :19-27
[18]  
Cutolo Maurizio, 2002, Autoimmunity Reviews, V1, P284, DOI 10.1016/S1568-9972(02)00064-2
[19]   Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis [J].
de Jong, BA ;
Westendorp, RGJ ;
Eskdale, J ;
Uitdehaag, BMJ ;
Huizinga, TWJ .
HUMAN IMMUNOLOGY, 2002, 63 (04) :281-285
[20]  
DERYCKE L, 2004, IN PRESS ANN RHEUM D